Aligos Therapeutics announces inducement grants under Nasdaq listing rule

Aligos Therapeutics (ALGS) announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase an aggregate of 4,000 shares of the Company’s stock to a newly hired employee on March 11, 2025, in connection with the commencement of employment. The Inducement Grant was granted pursuant to Aligos’ 2024 Inducement Plan as an inducement material to this individual entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos. The Inducement Grant has an exercise price per share equal to the closing price of Aligos’ common stock on the Grant Date. The shares subject to the Inducement Grant will vest over a four-year period, with 25% vesting on the first anniversary of the Grant Date and the remainder vesting in equal monthly installments, subject to the continued employment through the applicable vesting dates.